Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
The PBH news page on Stock Titan tracks announcements and disclosures from Prestige Consumer Healthcare Inc., a consumer healthcare products company listed on the New York Stock Exchange. Prestige issues frequent press releases covering its over-the-counter (OTC) brand portfolio, financial performance and corporate activities across the U.S. and Canada, Australia, and certain other international markets.
Investors and observers can use this news feed to follow quarterly and annual earnings releases, where Prestige reports revenues, net income, earnings per share, free cash flow, leverage and segment results for its North American OTC Healthcare and International OTC Healthcare businesses. These updates often highlight category trends such as gastrointestinal, women’s health, cough and cold, and eye and ear care, as well as the performance of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
The PBH news stream also includes announcements about investor conference participation, such as presentations at consumer staples and consumer growth and e-commerce conferences, and notices of upcoming earnings calls with webcast details. Corporate actions and regulatory topics appear as well, including the voluntary recall by Medtech Products Inc., a Prestige company, of specific lots of Little Remedies® Honey Cough Syrup due to microbial contamination, and communications about strategic transactions like the planned acquisition of Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and Clear Eyes® supplier.
By reviewing the PBH news page regularly, readers can see how Prestige describes its business priorities, category performance, capital allocation decisions such as share repurchases, and developments affecting its OTC healthcare brands and supply chain.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will issue its fiscal 2022 fourth quarter and year-end earnings on May 5, 2022, after market close. A conference call is scheduled for May 6 at 8:30 a.m. ET to discuss the results and company performance. Interested participants can join via phone or through an online webcast available on the company's Investor Relations page. Telephonic replays are accessible for a week post-call. Prestige Consumer Healthcare markets a variety of health products across North America and other markets.
Prestige Consumer Healthcare (NYSE:PBH) reported a 14.9% revenue increase to $274.5 million in Q3 2022, with a 22.2% rise in diluted EPS to $0.99. Nine-month revenues reached $819.9 million, up 16.2%. The company raised its full-year outlook, projecting revenue between $1,075 and $1,080 million, and adjusted EPS of $4.00 to $4.04. Strong performance stemmed from key brands, with increased demand in COVID-affected categories. Free cash flow for the quarter was $64.1 million, aiding in debt reduction.
Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2022 third quarter earnings on February 3, 2022, prior to market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results. U.S. and Canadian participants can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4798187. An internet webcast will be available, with a replay accessible from the Investor Relations page. Prestige markets a variety of consumer healthcare products including Monistat, BC, and Dramamine across several international markets.
Prestige Consumer Healthcare reported record revenue of $276.2 million for Q2 2022, a 16.3% increase from the previous year and 10.5% organic growth. The diluted EPS rose to $0.89, while adjusted EPS hit $1.02, reflecting a 30.8% year-over-year growth. Net operating cash flow was $61.2 million with adjusted free cash flow at $61.9 million. The company raised its full-year revenue and EPS guidance, anticipating total revenue between $1,050 million and $1,060 million while projecting adjusted EPS between $3.93 and $3.98.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2022 second quarter earnings on November 4, 2021, before market opening. A conference call to discuss the results is scheduled for the same morning at 8:30 a.m. ET, with dial-in options available for U.S. and international participants. An archived replay will be accessible on the company's Investor Relations page. Prestige Consumer Healthcare markets a diverse range of health products across North America and internationally.
Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2022 revenue of $269.2 million, marking a 17.3% increase from the previous year. Diluted EPS rose 32.5% to $1.14. Operating cash flow reached $69.3 million, while free cash flow was $67.8 million. The company raised its full-year outlook, projecting revenue of $1.045 billion or more and adjusted EPS of $3.90 or more, driven by solid brand performance and the recent acquisition of TheraTears, anticipated to add $40 million in revenue and $0.07 in EPS.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has finalized its acquisition of TheraTears and other consumer brands from Akorn Operating Company for $230 million in cash. The asset purchase is expected to enhance Prestige's eye care portfolio, bringing approximately $60 million in annual revenue and contributing $20 million in EBITDA. The transaction is valued at under 10x pro-forma EBITDA, providing anticipated tax benefits of ~$30 million. The acquisition was financed through available cash, an Asset Based Loan, and refinancing of its term loan maturing in 2028.
Prestige Consumer Healthcare (NYSE:PBH) announced a $230 million cash acquisition of a portfolio from Akorn Operating Company, including the TheraTears brand. This acquisition is projected to generate approximately $60 million in annual revenue and $20 million in EBITDA. The transaction, expected to close in fiscal Q2, offers tax benefits of about $30 million and is valued at less than 10x pro-forma EBITDA. The TheraTears brand, a leader in the dry eye segment, aligns with Prestige's growth strategy and operational model.
Prestige Consumer Healthcare (PBH) reported strong fiscal 2021 results, exceeding guidance with revenue of $943.4 million and record diluted earnings per share (EPS) of $3.25. In Q4, revenues were $237.8 million, down 5.4% year-over-year, while net income was $35.5 million. The company generated $213.4 million in adjusted free cash flow and provided a positive outlook for fiscal 2022, forecasting revenues of $957 to $962 million and adjusted EPS of $3.58 or more.
Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2021 fourth quarter and year-end earnings on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Participants can join via phone or listen to a webcast on the Investor Relations page of the company’s website. Telephonic replays will be available for a week post-call. Prestige markets various consumer healthcare products across North America and internationally, with well-known brands like Monistat®, Summer’s Eve®, and Dramamine®.